Daily Endocrinology Research Analysis
Three impactful endocrinology studies advance mechanistic and clinical understanding across metabolic and pituitary disorders. Obesity induces lasting islet endothelial VEGF-A desensitization that impairs insulin delivery (JCI). GLP-1–based therapies reduce liver fat and inflammation in MASLD/MASH across 25 RCTs (JCEM), while glucocorticoid-induced miR-375 downregulates SSTR2 and attenuates octreotide actions in corticotroph tumors (Endocrinology).
Summary
Three impactful endocrinology studies advance mechanistic and clinical understanding across metabolic and pituitary disorders. Obesity induces lasting islet endothelial VEGF-A desensitization that impairs insulin delivery (JCI). GLP-1–based therapies reduce liver fat and inflammation in MASLD/MASH across 25 RCTs (JCEM), while glucocorticoid-induced miR-375 downregulates SSTR2 and attenuates octreotide actions in corticotroph tumors (Endocrinology).
Research Themes
- Metabolic memory and islet microvascular dysfunction in obesity
- Incretin-based therapies for MASLD/MASH
- Epigenetic regulation of somatostatin receptor signaling in Cushing disease
Selected Articles
1. Diet-induced obesity promotes endothelial cell desensitization to VEGF-A and permanent islet vessel dysfunction in mice.
In a diet-induced obesity mouse model, islet endothelial cells became desensitized to VEGF-A, leading to persistent vessel barrier dysfunction and delayed insulin delivery. These changes were not fully reversed by diet normalization, reflecting a metabolic memory, and were mechanistically linked to atypical PKC–mediated inhibition of VEGFR2 internalization.
Impact: This study reveals a previously underappreciated vascular mechanism by which obesity impairs glucose homeostasis and identifies an actionable aPKC–VEGFR2 axis. It reframes islet dysfunction as a microvascular signaling problem with durable consequences beyond weight loss.
Clinical Implications: Therapeutic strategies that restore islet endothelial VEGF-A signaling, such as targeting atypical PKC or VEGFR2 trafficking, may improve insulin delivery and glucose handling after obesity. The data caution that weight loss alone may not normalize islet vascular function.
Key Findings
- Western diet (12 weeks) induced marked remodeling and VEGF-A desensitization of intra-islet endothelial cells.
- Islet vessel barrier dysfunction and hemodynamic dysregulation delayed insulin transit into the bloodstream.
- VEGF-A sensitivity and vascular alterations did not fully recover after diet normalization, impairing glucose clearance.
- Hyperactivation of atypical PKC inhibited VEGFR2 internalization, blunting VEGF-A signaling.
Methodological Strengths
- Longitudinal in vivo imaging of sentinel islets enabling time-resolved vascular phenotyping.
- Mechanistic dissection of VEGFR2 trafficking and aPKC signaling in endothelial cells.
Limitations
- Preclinical mouse model with islet transplantation into the eye may limit generalizability to human physiology.
- Clinical reversibility and therapeutic modulation were not tested in humans.
Future Directions: Validate the aPKC–VEGFR2 mechanism in human islets/tissues, develop modulators of endothelial VEGF-A signaling, and test whether restoring islet microvascular function improves glycemic outcomes after weight loss.
Pancreatic islet microvasculature is essential for optimal islet function and glucose homeostasis. However, islet vessel pathogenesis in obesity and its role in the manifestation of metabolic disorders remain understudied. Here, we depict the time-resolved decline of intra-islet endothelial cell responsiveness to VEGF-A and islet vessel function in a mouse model of diet-induced obesity. Longitudinal imaging of sentinel islets transplanted into mouse eyes revealed substantial vascular remodeling and diminished VEGF-A response in islet endothelial cells after 12 weeks of Western diet (WD) feeding. This led to islet vessel barrier dysfunction and hemodynamic dysregulation, delaying transportation of secreted insulin into the blood. Notably, islet vessels exhibited a metabolic memory of previous WD feeding. Neither VEGF-A sensitivity nor the other vascular alterations was fully restored by control diet refeeding, resulting in modest yet significant impairment in glucose clearance despite normalized insulin sensitivity. Mechanistic analysis implicated hyperactivation of atypical PKC under both WD and recovery conditions, which inhibited VEGFR2 internalization and blunted VEGF-A-triggered signal transduction in endothelial cells. In summary, prolonged WD feeding causes irreversible islet endothelial cell desensitization to VEGF-A and islet vessel dysfunction, directly undermining glucose homeostasis.
2. Efficacy of GLP-1-based Therapies on Metabolic Dysfunction-associated Steatotic Liver Disease and Metabolic Dysfunction-associated Steatohepatitis: A Systematic Review and Meta-analysis.
Across 25 RCTs (n=2600), GLP-1–based therapies significantly reduced liver fat, improved steatosis, ballooning, lobular inflammation, and liver enzymes, and improved liver stiffness in MASLD/MASH, without worsening fibrosis over a median of 24 weeks. Retatrutide showed the largest reductions in liver fat; tirzepatide evidence for histology was strongest among incretins.
Impact: This is the most comprehensive RCT-based synthesis to date showing multi-dimensional hepatic benefit of incretin-based agents in MASLD/MASH. It informs agent selection and endpoints for clinical practice and trial design.
Clinical Implications: For patients with MASLD/MASH (often with obesity/T2D), GLP-1/GIP agonists can be prioritized to reduce liver fat and inflammatory injury while improving enzymes and stiffness. Longer treatment is likely required for fibrosis; monitoring and adjunctive strategies should target fibrosis regression.
Key Findings
- 25 RCTs (n=2600) showed a 5.21% reduction in liver fat content over a median of 24 weeks.
- Histology improved for steatosis, ballooning, and lobular inflammation; fibrosis change was not significant.
- Liver enzymes (ALT, AST, GGT) and liver stiffness improved; no liver-related adverse safety signal observed.
- Retatrutide produced the largest LFC reduction; tirzepatide had the most robust histologic evidence.
Methodological Strengths
- Restricted to randomized controlled trials with multi-modal hepatic endpoints including imaging, histology, enzymes, and stiffness.
- Included a broad range of incretin agents allowing class- and agent-level insights.
Limitations
- Median treatment duration was short (≈24 weeks), limiting assessment of fibrosis regression.
- Heterogeneity across drugs, doses, and populations; head-to-head comparisons were limited.
Future Directions: Conduct longer RCTs powered for fibrosis endpoints, head-to-head comparisons among incretin agents, and combination trials targeting complementary antifibrotic mechanisms.
OBJECTIVE: New therapies are urgently needed for the treatment of metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH). We conducted this systematic review and meta-analysis to evaluate the therapeutic effects of glucagon-like peptide-1 receptor agonists (GLP-1RAs) on MASLD/MASH. METHODS: We searched PubMed, Embase, and Cochrane Library databases to identify randomized controlled trials (RCTs) that compared GLP-1RAs with placebo or active agents with respect to the efficacy in patients with MASLD/MASH. The effects of GLP-1RAs on liver fat content (LFC) by imaging, liver histology, serum liver enzymes, and noninvasive fibrosis indexes [Fibrosis-4, nonalcoholic fatty liver disease fibrosis score, cytokeratin 18, procollagen III, and liver stiffness) were evaluated. Mean differences and risk ratios with 95% confidence intervals were pooled using a random-effect model. RESULTS: Twenty-five RCTs involving 2600 patients who used GLP-1RAs including liraglutide, exenatide, dulaglutide, semaglutide, tirzepatide, efinopegdutide, survodutide, and retatrutide were included. Overall, GLP-1RAs treatment for a median of 24 weeks demonstrated a significant reduction in LFC by 5.21%, with retatrutide displaying the most obvious treatment effects. GLP-1RAs treatment induced significant histological improvements in steatosis, hepatocellular ballooning, and lobular inflammation but nonsignificantly improved fibrosis, with the evidence for tirzepatide more robust than that for semaglutide and liraglutide. GLP-1RAs treatment significantly decreased serum alanine aminotransferase, aspartate aminotransferase, and γ-glutamyl transferase compared with control. GLP-1RAs also significantly improved liver stiffness, with semaglutide displaying the most obvious treatment effect. No drug-related adverse effects involving the liver were observed. CONCLUSION: GLP-1RAs decreased liver fat deposition and improved histological steatosis, hepatocellular ballooning, and lobular inflammation, without worsening of fibrosis in MASLD and MASH.
3. miR-375 Regulation of SSTR2 Expression in Corticotroph Pituitary Cells: Somatostatin Receptor Ligands Effects.
Glucocorticoid exposure increases miR-375, which epigenetically downregulates SSTR2 in corticotroph tumors, impairing octreotide actions. Inhibition of miR-375 restores membranous SSTR2, enhances receptor internalization with octreotide, and augments antiproliferative/apoptotic signaling.
Impact: Identifying miR-375 as a GC-induced regulator of SSTR2 provides a mechanistic basis for octreotide resistance in Cushing disease and highlights a druggable epigenetic target to resensitize tumors.
Clinical Implications: Serum/tumor miR-375 may serve as a biomarker of SSTR2 status and octreotide responsiveness in corticotroph tumors. Therapeutic miR-375 inhibition could restore SSTR2 and enhance somatostatin ligand efficacy in Cushing disease.
Key Findings
- miR-375 levels were elevated in sera of Cushing disease patients and in human corticotroph tumors versus controls.
- Dexamethasone reduced SSTR2 gene expression; miR-375 inhibition increased membranous SSTR2 in AtT20 and primary human cultures.
- Combining octreotide with miR-375 inhibition enhanced receptor internalization, reduced proliferation, and increased apoptosis via PARP, Caspase-3, and ERK1/2 phosphorylation.
Methodological Strengths
- Integration of patient sera, tumor tissues, cell lines, and primary cultures to link clinical and mechanistic observations.
- Functional assays (WB/IF, proliferation, flow cytometry) establish causality between miR-375 and SSTR2 modulation.
Limitations
- Sample sizes for human cohorts were not detailed; findings are primarily in vitro/ex vivo without clinical outcome testing.
- No in vivo therapeutic validation of miR-375 inhibition in corticotroph tumor models.
Future Directions: Prospective studies correlating miR-375 levels with octreotide response; development and testing of safe miR-375 inhibitors; exploration of SSTR subtype interplay and combinatorial somatostatin ligand strategies.
Long-term exposure to glucocorticoids (GCs) downregulates SSTR2 expression in corticotroph tumors, limiting the efficacy of octreotide (OCT) in the treatment of Cushing disease (CD). In AtT20 cells, dexamethasone (DEX) increased the expression of miR-375, which has a seed sequence for Ssrt2, supporting the hypothesis that excessive GC exposure can lead to epigenetic SSTR2 downregulation. The current study aims to evaluate miR-375 levels by reverse transcription quantitative polymerase chain reaction in sera from patients with CD, human corticotroph pituitary tumors, normal pituitaries, and AtT20/D16 and GH3 cells, and miR-375 impact on SSTR2 expression in AtT20/D16 and human corticotroph pituitary tumors. SSTR2 protein expression and localization were evaluated by WB and IF in AtT20/D16 and human primary cultures. Proliferation assay and flow cytometry were assessed to investigate the impact of miR-375 regulation on OCT treatment in AtT20/D16. miR-375 levels were higher in sera from patients with CD than in healthy subjects, and in human corticotroph pituitary tumors than in normal pituitaries. AtT20/D16 and GH3 exhibited an inverse expression pattern, with SSTR2 mRNA at low levels and miR-375 at high levels in AtT20/D16 and an opposite expression pattern in GH3. DEX treatment significantly reduced SSTR2 gene expression, while miR-375 inhibition significantly increased SSTR2 membranous protein expression in AtT20/D16 and primary cultures. Receptor internalization appeared stronger when OCT was combined with miR-375 inhibitor. The decreased cell proliferation induced by OCT was potentiated by miR-375 inhibition, increasing cells in early and late apoptosis, by inducing PARP, Caspase3, and ERK1/2 phosphorylation. In conclusion, SSTR2 protein expression can be epigenetically downregulated by GC-induced miR-375 expression, at least partially influencing OCT action in corticotroph pituitary tumors.